Antibiotics in Inflammatory Bowel Disease: New Choices for an Old Disease

The American Journal of Gastroenterology

Volumn 89, Issue 7, 1994, Pages 974-978

  Spirt, Mitchell J ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLOFAZIMINE; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; METRONIDAZOLE; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; SALAZOSULFAPYRIDINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; TUBERCULOSTATIC AGENT;

ANAEROBIC INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; CROHN DISEASE; DRUG CHOICE; DRUG MIXTURE; ENTERITIS; GRAM NEGATIVE INFECTION; HUMAN; MYCOBACTERIOSIS; MYCOBACTERIUM PARATUBERCULOSIS; PRIORITY JOURNAL; REVIEW;

ANTIBIOTICS; HUMAN; INFLAMMATORY BOWEL DISEASES;

EID: 0028334149     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1994.tb03208.x     Document Type: Review

References (90)

1. Jejunal bacterial flora in chronic small bowel disease
2. Microbial flora of the upper small bowel in Crohn's disease
3. Studies on intestinal flora. part II
4. Bacteriological studies in Crohn's disease
5. Ulcerative colitis and intestinal salmonellosis
6. Influence of inflammatory bowel disease on intestinal microflora
7. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease
8. Campylobacter jejuni causing flare‐up in inflammatory bowel disease
9. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhea
10. Verocytotoxin‐producing Escherichia coli 02:H5 isolated from patients with ulcerative colitis
11. Relation between concentrations of metronidazole and Bacteroides spp. in faeces of patients with Crohn's disease and healthy individuals
12. Cell wall defective variants of Pseudomonas‐like (group Va) Bacteria in Crohn's disease
13. Bacterial L forms in inflammatory bowel disease
14. Preliminary report on isolation of mycobacteria from patients with Crohn's disease
15. Mycobacteria as a possible cause of inflammatory bowel disease
16. In vitro antimicrobial susceptibility of a Mycobacterium sp. isolated from patients with Crohn's disease
17. Bacterial activities of various antimicrobial agents against human and animal isolates of Mycobacterium paratuberculosis
18. Mycobacterial disease of the gut: Some impact from molecular biology
19. Mycobacteria and inflammatory bowel disease
20. Polymerase chain reaction (PCR) directly reports Mycobacterium paratuberculosis genomes in Crohn's disease tissue DNA extracts
21. Mycobacterium paratuberculosis and Avium subspecies silvaticum DNA cannot be detected in Crohn's disease tissues
22. Immunological aspects of inflammatory bowel disease
23. Microorganisms and their products in inflammatory bowel disease
24. Antimicrobial therapy of inflammatory bowel disease: Implications for pathogenesis and management
25. Cytokine‐mediated activation of vascular endothelium
26. The role of the mucosal immune system in inflammatory bowel disease
27. Secretion of a novel homolougus neutrophil‐activating peptide by LPS‐stimulated human endothelial cells
28. Effects of polymorphonuclear leukocyte transmigration on the barrier function of cultured intestinal epithelial monolayers
29. In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease
30. Granulocyte migration in ulcerative colitis
31. Indium 111‐granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease: A comparison with colonoscopy, histology, and fecal indium‐lll‐granulocyte excretion
32. Production of peptides inducing chemotaxis and lysosomal enzyme release in human neutrophils by intestinal bacteria in vitro and in vivo
33. Metronidazole for Crohn's disease
34. Regional enteritis
35. The fecal flora of patients with Crohn's disease
36. Elemental diets: Facts and fantasies
37. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis
38. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease
39. The effect of split ileostomy on perianal Crohn's disease
40. Loop ileostomy in the management of Crohn's colitis in the debilitated patient
41. Antibiotics in inflammatory bowel diseases
42. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease: A prospective randomized study
43. The efficacy of tobramycin in the treatment of ulcerative colitis
44. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis
45. Controlled trial comparing prednisolone with an elemental diet plus non‐absorbable antibiotics in active Crohn's disease
46. Advances in drug therapy for inflammatory bowel disease
47. Healing of perineal Crohn's disease with metronidazole
48. Metronidazole therapy for perineal Crohn's disease: A follow‐up study
49. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden. II. Result
50. Metronidazole in Crohn's disease: A double blind cross‐over clinical trial
51. Metronidazole therapy for Crohn's disease and associated fistulae
52. Metronidazole is more effective than placebo in treatment of active Crohn's disease
53. Double blind, placebo controlled trial of metronidazole in Crohn's disease
54. Evaluation of metronidazole in the management of Crohn's disease
55. Peripheral neuropathy in Crohn's disease patients treated with metronidazole: Who develops it
56. Peripheral neuropathy in Crohn's disease patients treated with metronidazole
57. Mycobacteria other than paratuberculosis may play a role in Crohn's disease
58. Antibodies to Mycobacterium paratuberculosis and nine species of environmental mycobacteria in Crohn's disease and control subjects
59. A Crohn's disease‐specific immune response to Mycobacterium paratuberculosis: Identification and characterization of two recombinant antigens
60. Gastrointestinal tuberculosis
61. Controlled trial of rifampicin and ethambutol in Crohn's disease
62. Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum
63. Use of rifabutin and streptomycin in the therapy of Crohn's disease
64. Antimycobacterial therapy and Crohn's disease: A randomized placebo controlled trial
65. Radiologic and clinical assessment of broad‐spectrum antibiotic therapy in Crohn's disease
66. Trimethoprim‐sulphamethoxazole therapy of inflammatory bowel disease
67. Colonization resistance of the digestive tract: Clinical consequences and implications
68. Anaerobes in intestinal homeostasis
69. Use of fluoroquinolones
70. Quinolone resistance: Susceptibility data from a 300‐bed community hospital
71. Wide‐spread resistant Staphylococcus aureus isolates in a general hospital
72. Rapid development of ciprofloxacin resistance in methicillin‐susceptible and ‐resistant Staphyloccus aureus
73. Emergence of resistance to fluoroquinolones in staphylococci: An alert
74. Methicillin‐resistant Staphyloccus aureus: A consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management
75. Changes in the pharmacokineties of ciprofloxacin and fecal flora during administration of a 7‐day course to human volunteers
76. A comparison of the pharmacokineties and tissue penetration of ciprofloxacin (oral and iv) and ofloxacin (oral) administered to volunteers, and comparison with in vitro activity (abstr S‐42‐1)
77. Eflect of Bay o 9867, a new quinolone antibacterial agent on human fecal flora (abstr 768)
78. Impact of floroquinolones on the gastrointestinal flora
79. Influence of oral ciprofloxacin or ofloxacin on the fecal flora of healthy volunteers
80. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: The eflect on fecal flora
81. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin
82. Current problems in antimicrobial therapy for bacterial enteric infection
83. Oral norfloxacin for prevention of Gram‐negative bacterial infections in patients with acute leukemia and granulocytopenia
84. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin
85. The imidazoles as immunosuppressive agents
86. Influence of new quinolones on normal immune capabilities
87. Ciprofloxacin may be useful in Crohn's disease
88. Long‐term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease
89. Is there a role for antibiotics as primary therapy in Crohn's ileitis
90. Inflammatory bowel disease: Back to the future